Roche Launches Quick-Administered Lung Cancer Immunotherapy in India
Roche brings 7-minute lung cancer shot to India
The Economic Times
Image: The Economic Times
Roche Pharma India has introduced the first injectable immunotherapy for lung cancer, allowing treatment in just seven minutes. Approved by the Drugs Controller General of India, the subcutaneous Tecentriq offers a significant reduction in hospital visit times for patients suffering from non-small cell lung cancer.
- 01Roche Pharma India has launched Tecentriq, the first injectable immunotherapy for lung cancer in India.
- 02The treatment can be administered in about seven minutes, a significant reduction from traditional intravenous methods.
- 03Lung cancer is a leading cause of cancer-related deaths in India, with approximately 80,000 new diagnoses each year.
- 04The cost of Tecentriq is around ₹3.7 lakh (approximately $4,500 USD) per dose.
- 05The new treatment method aims to ease the burden on patients and caregivers at crowded cancer centers.
Advertisement
In-Article Ad
Roche Pharma India has launched Tecentriq (atezolizumab), the first injectable immunotherapy for lung cancer, which can be administered in just seven minutes. This innovation, approved by the Drugs Controller General of India (DCGI), is designed for patients with adjuvant and metastatic non-small cell lung cancer (NSCLC). With a price of approximately ₹3.7 lakh (about $4,500 USD) per dose, Tecentriq significantly reduces the time patients spend in hospitals, which typically requires at least five hours per visit. This is particularly important as lung cancer is one of the top three causes of cancer-related deaths in India, with nearly 80,000 new cases diagnosed annually, many at advanced stages. The shorter administration time is expected to lessen the physical and emotional burden on patients and their caregivers, as stated by Sivabalan Sivanesan, chief medical officer at Roche Pharma India.
Advertisement
In-Article Ad
The introduction of Tecentriq is expected to significantly reduce the time lung cancer patients spend in hospitals, easing the strain on both patients and healthcare facilities.
Advertisement
In-Article Ad
Reader Poll
Do you think new cancer treatments should be prioritized in India?
Connecting to poll...
Read the original article
Visit the source for the complete story.